Tbx Genes Regulate Cell Cycle Partially Through Control of N-Myc Transcription
- 技術應用
- Potential therapies can be developed for the following by using T-box genes to control N-myc: Cancer treatments. Stem cell therapies to treat chronic and acute diseases. Genetic disorders involving T-box genes.
- 詳細技術說明
- Scientists at UC San Diego have discovered that T-box transcription factors, particularly Tbx2 and Tbx20, can regulate the role of N-myc in cells that are dependent on N-myc expression. The technology demonstrates that the induction or repression of T-box genes can regulate N-myc which, in turn, will be able to affect major developments in the cell, particularly the cell’s proliferation, cell cycle, and differentiation. Cells that are dependent on N-myc expression include many cellular types implicated in development, such as certain cancers and stem cells.
- *Abstract
-
The N-myc family of genes play a crucial role in the human body and is required for the growth and development of multiple organs, including the heart. The overexpression and amplification of N-myc is associated with a variety of tumors, most notably neuroblastomas and other childhood tumors. Despite its clinical relevance, little, if anything, is known as to which genes control expression of N-myc in vivo. The technology presented here provides evidence that N-myc expression can be regulated with T-box transcription factors (Tbx). T-box refers to a group of transcription factors that are expressed in a wide variety of tissue types and are involved in the development of diverse organs and tissues, particularly in the limbs and the heart. T-box genes also regulate patterning and cell fate, cell survival, and/or proliferation. Mutations in T-box genes are the cause of several congenital diseases and are implicated in cancer.
- *IP Issue Date
- Jul 19, 2011
- *Principal Investigation
-
Name: Chen-Leng Cai
Department:
Name: Ju Chen
Department:
Name: Sylvia Evans
Department:
Name: Michael Rosenfeld
Department:
Name: Wenlai Zhou
Department:
- 附加資料
- Patent Number: US7625874B2
Application Number: US2007734267A
Inventor: Evans, Sylvia | Chen, Ju | Cai, Chenleng | Zhou, Wenlai | Rosenfeld, Michael G
Priority Date: 11 Apr 2006
Priority Number: US7625874B2
Application Date: 11 Apr 2007
Publication Date: 1 Dec 2009
IPC Current: A61K004800 | C07H002102 | C07H002104 | C12N001563
US Class: 514044R | 514044 | 4353201 | 5360231 | 5360245
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for treating diseases associated with T-box and N-Myc
Usefulness: Compositions and methods for treating diseases associated with T-box and N-Myc
Summary: The method is useful in identifying a candidate N-Myc or Tbx2 upregulating compound or in treating cancer or heart disease (claimed).
Novelty: Identifying a candidate N-Myc or Tbx2 upregulating compound by contacting Tbx2 or Tbx20 with a known compound that binds Tbx2 or Tbx20 to form an assay mixture and determining the ability of the test compound to interact with Tbx2 or Tbx20
- 主要類別
- 診斷/治療
- 細分類別
- 癌症/腫瘤
- 申請號碼
- 7981615
- 其他
-
Intellectual Property Info
U.S. patent application filed 11-Apr-2007, published on 11-Oct-2007 (2007/0238692).
Related Materials
Tech ID/UC Case
19600/2005-223-0
Related Cases
2005-223-0
- 國家/地區
- 美國
欲了解更多信息,請點擊 這裡
